Brunescence in the aging canine lens

David Williams

Department of Veterinary Medicine, University of Cambridge, Cambridge, Cambs, UK

Brunescence, or lens browning, is a common finding in the ageing human lens but has not been reported to date in the dog. In the human brunescent in the aging lens correlates with the degree of protein thiolisation where photo-oxidation of sulphate groups yields disulphide bridges, a key step in age-related cataractogenesis which we know also occurs in the canine lens. Here the lenses of older dogs were examined to evaluate the amount of brunescence in the ageing canine lens.

20 lens from dogs of varying breeds and ages from 7 months to 13 years, with a mean age of 7.3±4.0 years were evaluated. Lenses were removed from eyes at post-mortem from dogs with eyes which, on ophthalmological examination pre-mortem, were unremarkable, barring nuclear sclerosis in dogs over 9 years of age but without overt cataract. Lenses were photographed against a white illuminated background and against a grid of lines. The resulted images were analysed using the NIH image analysis system Image J.

Efficacy of a cross-linked hyaluronic acid (HA) polymer on increasing healing rates of feline stromal corneal ulceration compared with a HA tear replacement drop: results of a masked controlled study

David Williams

Department of Veterinary Medicine, University of Cambridge, Cambridge, Cambs, UK

Topical hyaluronic acid (HA) gels have been widely used as a tear replacement but the beneficial effects of HA as a ligand for the CD44 cell surface receptor with regard to cell migration and adhesion suggest that a formulation with a prolonged corneal residence time may be valuable in promoting the healing of corneal ulcers. A cross-linked HA product (xCMHA-S; Remend Bayer) has been shown to stimulate corneal ulcer healing in an experimental rabbit model. Here we seek to ask whether topical xCMHA-S promotes healing of feline stromal ulceration more than a standard HA tear replacement drop in a masked controlled study.

30 cats affected with a stromal ulcer were included in the study. The animals were subject to a full systemic and ophthalmic examination and those with concurrent ocular or systemic disease were excluded from the study. Cats were randomly assigned to be treated with xCMHA-S or HA tear replacement drop (HATRD) three times daily together with topical antibiotic applied concurrently. The identity of the xCMHA-S or HATRD was masked since the product was identified only with a code number. Informed consent was provided by the owner. Re-examinations of each animal were conducted weekly until failure of the ocular surface to stain with fluorescein dye demonstrated ulcer healing. Time to ulcer healing was compared using an unpaired Students T test.

One cat was lost to follow up leaving 29 cats which fulfilled the trial, 15 animals treated with xCMHA-S and 14 with HATRD. The average age of the xCMHA-S-treated cats was 9.3±3.7 years while the age of the of the HATRD-treated cats was 8.6±2.1 years, these not significantly different at p=0.51. Eight of the ulcers treated with xCMHA-S were mid-stromal in depth with three being superficial stromal and four deep stromal. Of the HATRD-treated ulcers 13 were mid-stromal and one was deep stromal. The time to ulcer healing with xCMHA-S was 21±11 days and the time to healing with HATRD was 31.8±10.3 days, this significantly longer than for the xCMHA-S group at p=0.011.

This small study has shown that xCMHA-S reduces the healing time for feline stromal corneal ulceration by an average of 10 days. We suggest that the product can be a viable treatment for feline corneal stromal ulcers.